
    
      The objectives of this study are to establish 1-year safety and to investigate the effect of
      Sumifilam (PTI-125) on biomarkers, cognition and neuropsychiatric symptoms during 12-month
      repeat-dose oral administration in mild-to-moderate AD patients, 50-85 years of age.
    
  